Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AQST vs TLPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AQST Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–4 Matrix Metrics)

AQST Overall Winner 6-Pillar Tally: AQST 3 – 2 TLPH (1 Tie) Matrix Metrics: AQST 6 – 4 TLPH

As of Nov 16, 2026, Aquestive Therapeutics, Inc. (AQST) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AQST carries a Unified Composite Score of 59.4/100 (HOLD) at $3.77 (N/M Forward P/E, -114.1% operating margin), whereas TLPH carries 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin).

  • Growth vs. Quality Trade-Off: AQST earns the overall head-to-head edge with a stronger Unified Composite Score (59.4/100 HOLD vs. TLPH 37.1/100 SELL) and 0.87β · 56% Vol risk profile, whereas TLPH leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: AQST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.7); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AQST vs TLPH
AQST NASDAQ Head-to-Head Winner
Aquestive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.77
-3.45% 1D
Market Cap $448.7M
TTM Revenue $49M
Forward P/E N/M
Beta / 30D Vol 0.87β · 56% Vol
Unified Composite Score
59.4 / 100 HOLD
Tech 69.0 Fund 66.0 Flow 71.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.9%), weak momentum, RSI 44
RSI-14: 43.7 · SMA20: $3.85 · SMA50: $4.34
TLPH NASDAQ
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10

6-Pillar Scorecard Institutional Category Breakdown (AQST 3 – 2 TLPH)

Columns: Metric · AQST · TLPH
1. Valuation Multiples TLPH
Forward P/E N/M 1.0x
Trailing P/E N/M 1.0x
PEG Ratio N/M N/M
EV / Revenue 8.5x N/M
2. Growth & Scale AQST
Revenue Growth (YoY) -41.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $49M $1,000
Market Cap $448.7M $53.7M
3. Profitability & Quality AQST
Gross Margin 65.3% N/A
Operating Margin -114.1% -1474700.0%
Net Profit Margin -162.3% 0.0%
Return on Equity (ROE) 0.0% -143.4%
4. Balance Sheet & Cash Flow AQST
Cash Generation (TTM) -$41M -$15M EBITDA
Cash Flow Margin -83.3% N/A
Net Cash / Leverage $32M Net Cash $0.28 Book/Sh · -143.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TLPH
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 61.9% (40th %ile) 118.4% (100th %ile)
Put/Call OI Skew 0.38x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AQST (6) vs TLPH (4)
Institutional Metric AQST TLPH Criterion Row Edge
Market Capitalization
Scale
$448.7M $53.7M Larger Scale AQST
Trailing P/E Ratio
Valuation
N/M 1.0x Lower Multiple TLPH
Forward P/E Ratio
Valuation
N/M 1.0x Lower Multiple TLPH
Revenue Growth (YoY)
Growth
-41.0% +0.0% Higher Growth TLPH
Operating Margin (TTM)
Profitability
-114.1% -1474700.0% Higher Margin AQST
Net Profit Margin
Profitability
-162.3% 0.0% Higher Margin TLPH
Return on Equity (ROE)
Capital Efficiency
0.0% -143.4% Higher ROE AQST
52-Week Range Position
Momentum
22% ($3–$7) 20% ($1–$2) Stronger Trend AQST
Beta / 30D Volatility
Risk Regime
0.87β · 56% Vol 1.11β · 58% Vol Lower Realized Risk AQST
Unified Institutional Score
Composite Signal
59.4 / 100 (HOLD) 37.1 / 100 (SELL) Higher Composite AQST
Trailing 12M Revenue (USD)
Operating Scale
$49M $1,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 8.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$41M ($32M Net Cash) -$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AQST +20.16 pp
AQST: -0.13% · TLPH: -20.29%
3M Horizon AQST +16.23 pp
AQST: -12.62% · TLPH: -28.85%
6M Horizon TLPH +16.69 pp
AQST: -8.71% · TLPH: +7.98%
1Y Horizon TLPH +10.76 pp
AQST: -28.77% · TLPH: -18.01%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AQST vs TLPH. Trailing 12-month operating profitability (AQST -114.1% vs TLPH -1474700.0%) and valuation multiples (AQST N/M vs TLPH 1.0x Forward P/E) are benchmarked directly in Pillar 4 below.

AQST ADR TTM Benchmark FX-Normalized USD
TTM Revenue$49M
Gross Margin65.3%
Op. Margin-114.1%
ROE / Fwd P/E0.0% · N/M
TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AQST BREAKDOWN
57d in phase · OBV DISTRIBUTION
Current IV 61.9%
IV Percentile 40th %ile
Put/Call OI Skew 0.38x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AQST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AQST Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $448.7M market capitalization and -114.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AQST vs TLPH Key Questions & Quantitative Answers

As of Nov 16, 2026, Aquestive Therapeutics, Inc. (AQST) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AQST carries a Unified Composite Score of 59.4/100 (HOLD) at $3.77 (N/M Forward P/E, -114.1% operating margin), whereas TLPH carries 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin). Growth vs. Quality Trade-Off: AQST earns the overall head-to-head edge with a stronger Unified Composite Score (59.4/100 HOLD vs. TLPH 37.1/100 SELL) and 0.87β · 56% Vol risk profile, whereas TLPH leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AQST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.7); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AQST leads the Growth & Scale pillar: AQST posts -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin), compared with TLPH at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin). On trailing 12-month operating scale, AQST generates $49M in USD-normalized revenue versus $1,000 for TLPH. In operating R&D and SG&A reinvestment, AQST deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TLPH.

TLPH screens cheaper on headline valuation multiples. AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.5x EV/Revenue (-83.3% FCF margin), whereas TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AQST (0.0% ROE) versus TLPH (-143.4% ROE) capital efficiency.

In options market volatility and institutional positioning, AQST carries 61.9% implied volatility (40th %ile, Balanced (25th–60th %ile)), a 0.38x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.87β · 56% Vol realized risk). By comparison, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.